Trial Information

Summary: Painful Peripheral Neuropathy

This study is a 15-week, placebo-controlled trial comparing the efficacy, safety, and tolerability of Pregabalin versus placebo. The study is designed to evaluate the efficacy of Pregabalin in reducing neuropathic pain associated with HIV infection. Pregabalin is an FDA-approved drug for Diabetic Peripheral Neuropathy. All participants will receive monitoring throughout the study period.

Patient Inclusion Criteria

• Male or female adults at least 18 years of age
• Documented diagnosis of HIV-1 infection
• Neuropathic pain associated with HIV infection for longer than 3 months

Patient Exclusion Criteria

• Pregnant/lactating females

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 6:32:50 AM